Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Shanghai Jiao Tong University School of Medicine

Status

Completed

Conditions

Diabetic Nephropathy

Angiotensin II Type 1 Receptor Blockers

Obese

Glucose Metabolism

Type 2 Diabetes

Treatments

Drug: losartan

Study type

Interventional

Funder types

Other

Identifiers

NCT00561704

ADL

Details and patient eligibility

About

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Full description

it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Enrollment

80 patients

Sex

Female

Ages

30+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria